Nautilus Biotechnology Announces Participation In SEEDS Research Consortium, Which Was Awarded Up To $51.7M By The Advanced Research Projects Agency For Health
Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering intact, single-molecule proteomics approaches, today announced its participation in SEEDS (Sequence-to-disease: Environment-aware Ensembles of Disordered
Nautilus joined a research group that won up to $51.7 million in government funding. This shows the company's science is trusted by big health experts.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.